• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:ONC)

228.38 +2.61 (+1.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 290,199
Open 227.63
Bid (Size) 220.00 (1)
Ask (Size) 242.00 (1)
Prev. Close 225.77
Today's Range 227.05 - 230.58
52wk Range 172.67 - 287.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
May 14, 2025
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2025
From BeiGene, Ltd.
Via Business Wire

Performance

YTD
+24.1%
+24.1%
1 Month
-1.1%
-1.1%
3 Month
-4.1%
-4.1%
6 Month
+24.1%
+24.1%
1 Year
+24.1%
+24.1%

More News

Read More
Earnings Scheduled For May 7, 2025
May 07, 2025
Via Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
Via Benzinga
Earnings Scheduled For May 14, 2025
May 14, 2025
Via Benzinga
Earnings Preview: BeiGene
May 13, 2025
Via Benzinga
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
May 07, 2025
Via Benzinga
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
May 07, 2025
From BeiGene, Ltd.
Via Business Wire
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
April 29, 2025
From BeiGene, Ltd.
Via Business Wire
Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back
April 26, 2025
Via Benzinga
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
April 23, 2025
Via Stocktwits
Why Is Summit Therapeutics Stock Soaring On Wednesday?
April 23, 2025
Via Benzinga
BeiGene to Announce First Quarter 2025 Financial Results on May 7
April 17, 2025
From BeiGene, Ltd.
Via Business Wire
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
April 11, 2025
Via Benzinga
Forecasting The Future: 4 Analyst Projections For BeiGene
April 10, 2025
Via Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
April 07, 2025
Via Benzinga
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
April 03, 2025
Via Benzinga
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
April 03, 2025
From BeiGene, Ltd.
Via Business Wire
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket
March 27, 2025
Via Benzinga
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
March 26, 2025
Via Benzinga
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
March 18, 2025
Via Benzinga
Earnings Scheduled For March 7, 2025
March 07, 2025
Via Benzinga
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
March 04, 2025
Via Benzinga
Exposures Product Safety
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
March 04, 2025
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
February 27, 2025
From BeiGene, Ltd.
Via Business Wire

Frequently Asked Questions

Is BeiGene, Ltd. - American Depositary Shares publicly traded?
Yes, BeiGene, Ltd. - American Depositary Shares is publicly traded.
What exchange does BeiGene, Ltd. - American Depositary Shares trade on?
BeiGene, Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BeiGene, Ltd. - American Depositary Shares?
The ticker symbol for BeiGene, Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market
What is the current price of BeiGene, Ltd. - American Depositary Shares?
The current price of BeiGene, Ltd. - American Depositary Shares is 228.38
When was BeiGene, Ltd. - American Depositary Shares last traded?
The last trade of BeiGene, Ltd. - American Depositary Shares was at 05/16/25 04:00 PM ET
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap